Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis

Vaccine

Volumn 27, Issue 42, 2009, Pages 5755-5759

  Jacobsson, Susanne ^a   Mölling, Paula ^a   Olcén, Per ^a  

^a National Reference Laboratory for Pathogenic Neisseria   (Sweden)

Author keywords

Factor H binding protein (fHbp); Neisseria adhesin A (NadA); Neisseria meningitidis; Seroprevalence; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; CROSS REACTING ANTIGEN; FACTOR H BINDING PROTEIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEISSERIA ADHESION A3 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CHILD; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; INCIDENCE; MALE; NEISSERIA MENINGITIDIS; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROPREVALENCE; SWEDEN;

ADHESINS, BACTERIAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS INFLUENZAE TYPE B; HUMANS; IMMUNOGLOBULIN G; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; SEROEPIDEMIOLOGIC STUDIES; SWEDEN; YOUNG ADULT;

EID: 69749086382     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.056     Document Type: Article

References (39)

1. Stephens D.S., Greenwood B., and Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369 9580 (2007) 2196-2210
2. Trotter C.L., McVernon J., Ramsay M.E., Whitney C.G., Mulholland E.K., Goldblatt D., et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26 35 (2008) 4434-4445
3. Morris S.K., Moss W.J., and Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 8 7 (2008) 435-443
4. Pletz M.W., Maus U., Krug N., Welte T., and Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32 3 (2008) 199-206
5. Trotter C.L., and Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31 1 (2007) 101-107
6. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31 1 (2007) 27-36
7. Coen P.G., Cartwright K., and Stuart J. Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica. Int J Epidemiol 29 1 (2000) 180-188
8. Pollard A.J., and Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 19 11-12 (2001) 1327-1346
9. Glode M.P., Robbins J.B., Liu T.Y., Gotschlich E.C., Orskov I., and Orskov F. Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis 135 1 (1977) 94-104
10. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129 6 (1969) 1327-1348
11. Grados O., and Ewing W.H. Antigenic relationship between Escherichia coli and Neisseria meningitidis. J Infect Dis 122 1 (1970) 100-103
12. Kasper D.L., Winkelhake J.L., Zollinger W.D., Brandt B.L., and Artenstein M.S. Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol 110 1 (1973) 262-268
13. Mitchell M.S., Rhoden D.L., and King E.O. Lactose-fermenting organisms resembling Neisseria meningitidis. J Bacteriol 90 (1965) 560
14. Reller L.B., MacGregor R.R., and Beaty H.N. Bactericidal antibody after colonization with Neisseria meningitidis. J Infect Dis 127 1 (1973) 56-62
15. Vann W.F., Liu T.Y., and Robbins J.B. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun 13 6 (1976) 1654-1662
16. Smith M.J. Meningococcal tetravalent conjugate vaccine. Expert Opin Biol Ther 8 12 (2008) 1941-1946
17. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 8775 (1991) 1093-1096
18. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., and Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23 17-18 (2005) 2191-2196
19. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281 16 (1999) 1520-1527
20. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103 29 (2006) 10834-10839
21. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72 4 (2004) 2088-2100
22. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., and Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27 21 (2009) 2794-2803
23. Jacobsson S., Thulin S., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 24 12 (2006) 2161-2168
24. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177 1 (2006) 501-510
25. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 6 (2003) 789-799
26. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195 11 (2002) 1445-1454
27. Comanducci M., Bambini S., Caugant D.A., Mora M., Brunelli B., Capecchi B., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 72 7 (2004) 4217-4223
28. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55 3 (2005) 687-698
29. Franzoso S., Mazzon C., Sztukowska M., Cecchini P., Kasic T., Capecchi B., et al. Human monocytes/macrophages are a target of Neisseria meningitidis adhesin A (NadA). J Leukoc Biol 83 5 (2008) 1100-1110
30. Mazzon C., Baldani-Guerra B., Cecchini P., Kasic T., Viola A., de Bernard M., et al. IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol 179 6 (2007) 3904-3916
31. Kayhty H., Peltola H., Karanko V., and Makela P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147 6 (1983) 1100
32. Spanjaard L., and Rijkers G.T. Haemophilus influenzae serotype b vaccine failure: what is the significance of antibody levels?. Clin Infect Dis 49 3 (2009) 381-382
33. Cartwright K.A., Stuart J.M., Jones D.M., and Noah N.D. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99 3 (1987) 591-601
34. Caugant D.A., Hoiby E.A., Magnus P., Scheel O., Hoel T., Bjune G., et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 32 2 (1994) 323-330
35. Claus H., Maiden M.C., Wilson D.J., McCarthy N.D., Jolley K.A., Urwin R., et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191 8 (2005) 1263-1271
36. Trotter C., Findlow J., Balmer P., Holland A., Barchha R., Hamer N., et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 14 7 (2007) 863-868
37. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 5459 (2000) 1816-1820
38. Litt D.J., Savino S., Beddek A., Comanducci M., Sandiford C., Stevens J., et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 190 8 (2004) 1488-1497
39. Jacobsson S., Hedberg S.T., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 27 10 (2009) 1579-1584